Abstract：Objective : To investigate the influence factors of poor treatment in patients with gastroesophageal reflux disease.Methods : Outpatients who used PPI (proton pump inhibitor) for more than 8 weeks in initial treatment of anti reflux therapy from January 2013 to January 2014 were involved. The medicines usage were collected and analyzed using questionnaires. Results : In patients with exceeding body mass index, irregular and intermittent medication, diet without adjustment, lifestyle without adjustment, and combined constipation, are the participation factors of GERD patients, which in the treatment course of more than 8 weeks. Conclusion : Patients with poor therapeutic effect and drug withdrawal difficult, in addition to consider drug factors, but also need to strengthen the supervision of medication adherence and diet life style education, control obe sity, and treat constipation.
[1] Sandier R S, Everhart J E, Donowitz M, et al.The burden of selected digestive diseases in the United States[J].Gastroenterology, 2002,122(5):1500-1511．
[2] Wong B C, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia[J].Clin Gastroenterol Hepatol, 2006, 4(4):398-407.
[3] Dent J, Jones R, Kahrilas P, et al.Management of gastro-esophageal reflux disease in general practice[J].BMJ, 2001, 322(7282):344-347.
[4] 吴昭君, 刘世坤, 易爱纯, 等. 2008~2010 年某医院质子泵抑制剂的应用分析[J]. 药品评价, 2012, 09(8):28-31.
[5] Klinkenberg-Knol E C, Nelis F, Dent J, et al.Long-Term omeprazole treatment in resistant gastroesophageal reflux disease efficacy,safety,and influence on gastric mucosa[J]. Gastroenterology, 2000,118(4):661-669.
[6] Targownik L E, Metge C, Roos L, et al.The prevalence of and the clinical and demographic characteristics associated with highintensity proton pump inhibitor use[J].Am J Gastroenterol, 2007,102(5):942-950．
[7] Crawley J A,Schmitt C M. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Study[J]. J Clin Outcomes Manag, 2000, 7(11):29-34.
[8] Fass R, Sifrim D. Management of heartburn not responding to proton pmnp inhibitors[J]. Gut, 2009, 58(2):295-309．
[9] Ghebremariam Y T, LePendu P, Lee J C, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine[J]. Circulation, 2013, 128:845-853.
[10] Muriithi A K, Leung N, Valeri A M, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series[J]. Am J Kidney Dis 2014; 64(4):558-666.
[11] Lam J R, Schneider J L, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency[J]. JAMA, 20 13, 310(22):2435-2442.
[12] Fletcher J, Derakhshan M H, Jones G R, et al. BMI is superior to symptoms in predicting response to proton pump inhibitor:randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy[J].Gut, 2011, 60(4):442-448.
[13] Ness-Jensen E, Lindam A, Lagergren J, et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study[J]. Am J Gastroenterol, 2013,108(3):376.
[14] Ness-Jensen E, Lindam A, Lagergren J,et al. Tobacco smoking cessation and improved gastroesophageal Reflux: a prospective population-based cohort study: the HUNT study[J]. Am J Gastroenterol, 2013 Dec 10. doi:10.1038/ajg. 2013. 414.
[15] Lee S W, Chang C M, Chang C S, et al.Comparison of presentation and impact on quality of life of gastroesophageal reflux disease between young and old adults in a Chinese population [J].World J Gastroenterol, 2011, 17(41):4614-4618.
[16] Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-thecounter proton pump inhibitors in patients with gastroesophageal reflux disease[J]. Am J Gastroenterol, 2014, 109(6):789-794.
2016, Vol. 14 
